Shots:

• Oxford Biomedica to receive $10M up front in cash- ~$86M as development and regulatory milestones- ~ $131M as commercial milestones and royalties on sales of products developed by Juno Therapeutics utilizing the LentiVector platform
• Oxford Biomedica will also receive payments from process development and scale-up projects as well as relating to the GMP manufacture of lentiviral vectors for use in clinical trials. Additionally- Juno gets access to Oxford’s new 7-800 m² manufacturing centre- OxBox and allow it to initiate additional projects in the future
• The LSA provides Juno a non-exclusive license to Oxford’s LentiVector platform for its application in CAR-T and TCR-T programs in oncology and other indications and additionally enters into a 5yrs. clinical supply agreement that can be extended further

Click here ­to­ read full press release/ article | Ref: Oxford Biomedica | Image: Juno Therapeutics